Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Piotroski F-score
Gilead Sciences, Inc.'s Piotroski F-score for fiscal 2025 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, up from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 8 | 1.00 |
| FY2024 | 7 | 0.00 |
| FY2023 | 7 | (1.00) |
| FY2022 | 8 | 1.00 |
| FY2021 | 7 | 1.00 |
| FY2020 | 6 | (2.00) |
| FY2019 | 8 | 1.00 |
| FY2018 | 7 | 2.00 |
| FY2017 | 5 | 0.00 |
| FY2016 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 14.42% | 0.79% | Pass | 1 |
| Positive operating cash flow | 10.02b | 10.83b | Pass | 1 |
| Rising return on assets | 14.42% | 0.79% | Pass | 1 |
| Cash flow above net income | 1.51b | 10.35b | Pass | 1 |
| Falling long-term leverage | 0.38 | 0.41 | Pass | 1 |
| Rising current ratio | 1.55 | 1.60 | Fail | 0 |
| No new shares issued | 1,244,000,000 | 1,247,000,000 | Pass | 1 |
| Rising gross margin | 78.83% | 78.26% | Pass | 1 |
| Rising asset turnover | 0.50 | 0.47 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AZN AstraZeneca PLC compare | 9 |
| BMY Bristol Myers Squibb Company compare | 8 |
| NVS Novartis AG compare | 8 |
| GILD Gilead Sciences, Inc. | 8 |
| AMGN Amgen Inc. compare | 7 |
| SNY Sanofi compare | 7 |
| PFE Pfizer Inc. compare | 6 |
| NVO Novo Nordisk A/S compare | 5 |
| MRK Merck & Co., Inc. compare | 4 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement